T. Rowe Price’s New Active Biotech and Small-Cap ETFs Might Change The Case For Investing In TROW

T. Rowe Price recently expanded its exchange traded lineup by launching three fully transparent, actively managed equity ETFs on NASDAQ: a biotech ETF (TDNA, expense ratio 0.55%), a small-cap ETF (TSEE, 0.59%), and a mid-cap equity research ETF (TMID, 0.47%). This push into biotech, small-cap, and mid-cap active ETFs highlights T. Rowe Price’s effort to broaden its product set and reach new types of investors. We’ll now examine how this active ETF expansion, especially the biotech-focused...